The Wilms' tumour suppressor gene, WT1, encodes a zinc-finger protein that is mutated in Wilms' tumours and highly expressed in a wide variety of other malignancies. WT1 is a transcription factor that is likely to have additional, post-transcriptional, regulatory roles, although the molecular mechanisms by which WT1 acts remain poorly understood. We have combined genetic and biochemical approaches to show, that endogenous WT1 binds to heterogeneous nuclear ribonuclear protein U (hnRNP-U), that this interaction does not require any other proteins or nucleic acids, involves the zinc-fingers of WT1 and the middle domain of hnRNP-U, and that hnRNP-U can modulate WT1 transcriptional activation of a bona fide WT1 target gene. These findings increase our knowledge of how WT1 exerts its transcriptional regulatory role and suggests that hnRNP-U may be a candidate Wilms' tumour gene at 1q44.
Wilms' tumour is a paediatric kidney malignancy of embryonic origin that has an incidence of one out of 10 000 infants (Breslow et al., 1988) . It serves as a striking example of cancer arising through inappropriate development (Hastie, 1994) . The search for genes associated with Wilms' tumour led to the identification by positional cloning of the Wilms' tumour suppressor gene, WT1, at 11p13 (Call et al., 1990; Gessler et al., 1990) . The WT1 gene has been extensively studied and has shown to play a direct role in the aetiology of Wilms' tumour. Approximately 10-15% of sporadic Wilms' tumours carry mutations in the WT1 gene, and also humans with germline mutations in WT1 have a predisposition to Wilms' tumours and developmental malformations of the urogential system (Rivera and Haber, 2005) . Furthermore, high levels of wild-type WT1 protein can be found in a variety of human malignancies, for example, leukaemia (Bergmann et al., 1997) , breast (Loeb et al., 2001) , lung (Oji et al., 2004) , colon (Oji et al., 2003) and skin cancer (Rodeck et al., 1994) , and downregulation of WT1 has been shown to inhibit in vitro proliferation of leukaemia (Yamagami et al., 1996) and breast cancer cells (Zapata-Benavides et al., 2002) .
Understanding the precise function of WT1 is complicated by the fact that alternative splicing and translation initiation produces numerous protein isoforms, all of which are nuclear proteins containing four C 2 H 2 zinc-finger motifs. Transfection of individual WT1 isoforms can have dramatic cellular consequences and affect expression of a large number of genes (Little et al., 1999) . However, these findings should be viewed with caution as the effect of WT1 transfection can vary with the cell type and promoter used as well as with the particular isoform (Reddy and Licht, 1995) . To date, only the þ /ÀKTS isoforms (a three amino-acid alternative splicing event between the third and fourth zinc-finger) have been shown to play an important role in vivo (Hammes et al., 2001 , Natoli et al., 2002 Miles et al., 2003) . It is likely that for normal WT1 function, the full complement of endogenously expressed isoforms is required. This hypothesis is consistent with the observation that Frasier syndrome (male pseudohermaphroditism and progressive glomerulopathy) is caused by a loss of þ KTS isoform expression from only one allele, thereby subtly altering the þ /ÀKTS ratio (Barbaux et al., 1997) .
To understand the molecular pathways by which WT1 mutation causes Wilms' tumour and Frasier syndrome requires the identification of downstream target genes and interacting proteins. Furthermore, these target genes and interacting proteins are likely to be candidates for Wilms' tumour predisposition genes involved in the B85% of Wilms' tumours that lack WT1 lesions and may help to understand the role of high levels of WT1 in a range of malignancies.
It has been shown that, in addition to acting as a classical DNA-binding transcription factor, WT1 may play a role in post-transcriptional events as it has been shown to bind RNA, colocalizes with splicing factors and has been shown to bind directly to U2AF65 (Larsson et al., 1995; Caricasole et al., 1996; Davies et al., 1998) . However, no direct RNA targets have been identified so far. The majority of studies to date have focused on identifying transcriptional targets of WT1, although as WT1-transfected cell lines are not a physiologically relevant system, very few bona fide WT1 target genes have been identified. Those that have include amphiregulin, SF-1, Wnt-4, nephrin and TrkB (Lee et al., 1999; Wilhelm and Englert, 2002; Sim et al., 2002; Wagner et al., 2004 Wagner et al., , 2005 ) and the situation is further complicated by the fact that WT1 activity is likely to be modulated by its interactions with other proteins. For example, WT1 interacts with steroidogenic factor 1 (SF-1) to activate mullerian inhibitory substance (MIS) expression in the male gonadal ridge, but this interaction is antagonized by the X-linked sex reversal protein, Dax1, which competes WT1 off SF-1, thereby inactivating the complex (Nachtigal et al., 1998) . Thus to fully understand the function of WT1 at the molecular level, it is necessary to identify the proteinbinding partners of WT1.
WT1 has been shown to interact with numerous proteins (Roberts, 2005 ) that could modulate transcription including DNA-binding transcription factors (p53, p63, p73, Hsp70, BMZF2, SF-1, SRY) and cofactors that could act as transcriptional co-regulators (Par-4, Ciao-1, WTIP, CBP and Basp-1). Typically, these interacting proteins were identified by yeast two-hybrid screening or affinity purification with immobilized WT1 peptides (Roberts, 2005) . Although these indirect approaches have identified numerous protein partners, to date there is no report of interacting proteins identified by co-immunoprecipitation of endogenous WT1 complexes. The approach taken in this report was to immunoprecipitate endogenous WT1-containing complexes from retinoic acid-induced monolayer cultures of differentiating embryonic stem (ES) cells and identify directly the associated proteins by Maldi-time of flight (TOF) analysis. During retinoic acid differentiation, monolayer ES cell cultures have been demonstrated to express the normal repertoire of WT1 isoforms (Scharnhorst et al., 1997) . Therefore, combining this system with Maldi-TOF analysis, we are able to identify WT1 interacting proteins in their normal physiological context in non-transformed cells.
To create a physiologically relevant system with which to identify WT1 target genes and interacting proteins, we established Wt1-null ES cells lines to serve as a negative control for the analysis of endogenous WT1 in retinoic acid-induced ES cell differentiation (Figure 1a) . We employed sequential rounds of gene targeting in E14 (iv) ES cells to remove both copies of exon 1 of Wt1 (details available on request). Two independent Wt1-null ES cell lines were established, LK1 and LK46, as verified by Southern blot analysis (data not shown). As predicted, these mutations completely abolish WT1 protein expression in ES clones differentiated for 96 h with all-trans retinoic acid (ATRA), as determined by Western blot for WT1 (Figure 1b) .
Immunoprecipitates (IPs), using the anti-WT1 rabbit polyclonal C-19 from wild-type and mutant control (LK1) ES cell lines differentiated for 96 h with ATRA, were analysed by Western blot to confirm WT1 immunoprecipitation from E14 nuclear extract but not from LK1 nuclear extract (Figure 2a) . These samples were then separated on a gradient SDS-PAGE gel and stained with Coomassie Blue (Figure 2b ). Bands appearing in the wild-type IP but not in the WT1-null IP ( Figure 2b ) were excised along with the corresponding regions from the control lane. Following in-gel tryptic protein digestion, peptides were analysed by Maldi-TOF mass spectrometry and proteins identified by matching the observed proteolytic masses with the NCBI non-redundant protein database (MS-FIT) ( Figure 2b ). L1 was shown to be highly similar to heterogeneous nuclear ribonucleoprotein U (hnRNP-U) and L4 showed high similarity to either g-or b-actin. The corresponding regions from WT1-null IPs produced In this study we focus on hnRNP-U, the largest member (120 kDa) of the hnRNP protein family, which bind pre-mRNA and nuclear mRNA and play an important role in processing and transport of mRNA (Krecic and Swanson, 1999) . hnRNP-U is an abundant protein, with approximately 50% of cellular hnRNP-U associated with the nuclear matrix, via binding to scaffold attachment region sequences and hence is also know as Scaffold Attachment Protein A (SAF-A) (Romig et al., 1992) . The rest of hnRNP-U is associated with chromatin or found in the hnRNP particles (Kiledjian and Dreyfuss, 1992) .
To confirm the interaction between WT1 and hnRNP-U, we performed reciprocal IPs from ATRAdifferentiated E14 ES cells using either a mouse monoclonal antibody specific for hnRNP-U (3G6; Gift Dr G Dreyfuss) or the WT1 rabbit polyclonal C-19 antibody followed by immunoblotting with the reciprocal antibody (Figure 3a and c) . These experiments confirmed that the proteins co-precipitated and that a significant fraction of both proteins is associated within a physical complex within the nucleus. Identical results were observed when carrying out immunoprecipitations for endogenous WT1 and hnRNP-U from the M15 mouse mesonephric kidney cell line (Ladomery et al., 1999) (Figure 3b and d) . As expected, hnRNP-U could not be immunoprecipitated from WT1-null ES cells, even though these cells express comparable levels of hnRNP-U compared to wild-type (data not shown), nor could hnRNP-U be immunoprecipitated in the control IPs using pre-immune rabbit immunoglobulin G (IgG) (Figure 3) . Nuclear extracts for immunoprecipitation were routinely treated with both DNase and RNase, suggesting that the interaction between WT1 and hnRNP-U was not dependent on the presence of nucleic acids. Furthermore, deconvolution microscopy demonstrated that endogenous hnRNP-U was present within the nucleus of the M15 cells and that a significant Nuclear extracts were prepared from ATRA-differentiated monolayer cultures of E14 (iv) and LK1 embryonic stem cells and pre-cleared with sepharose beads, then incubated with immobilized anti-WT1 rabbit polyclonal antibody (C-19; Santa Cruz) overnight at 41C. Equivalent amounts of WT1 immunoprecipitates from E14 (iv) and LK1 were resolved and probed with anti-WT1 mouse monoclonal antibody (6F-H2; Dako) for the presence of WT1. T, total nuclear extract; UN, unbound fraction; E1, first elution; E2, second elution. (b) Identification of WT1 associated protein by mass spectrometry. WT1 immunoprecipitates (20 mg) from E14 (iv) and LK1 were resolved on a gradient NuPAGE 4-12% Bis-Tris Gel (Invitrogen) along with a Mark12-unstained standard marker (Invitrogen). Proteins were visualized by Coomassie Blue stain (Genomic Solutions). Protein bands annotated as L1-L4 were excised from the gel along with the corresponding regions from the LK1 lane and peptide fingerprint analysis was carried out using an Applied Biosystems Voyager DEt STR Maldi-TOF instrument. Interpretation of data was preformed using the Voyager V5 Data Explorer software and database searching performed using the Protein Prospector MS-Fit program (http://prospector.ucsf.edu/). (Figure 3e ). To examine potential colocalization in vivo, double immunofluorescence was performed on developing murine kidneys. WT1 is initially expressed throughout the developing metanephric mesenchyme until becoming restricted to developing glomeruli (Armstrong et al., 1993) . hnRNP-U is ubiquitously expressed and was present in all components of the developing kidney, although at higher levels in the developing glomeruli along with WT1 ( Figure 3f ). This finding is consistent with the recent data of Challen et al. (2005) who showed hnRNP-U levels to be fivefold higher in condensed mesenchyme compared with ureteric bud and our colocalization supports the idea that WT1 and hnRNP-U interact in vivo (Challen et al., 2005) .
To further probe the nature of the interaction between WT1 and hnRNP-U, we performed in vitro glutathione-S-transferase (GST)-binding assays using bacterially purified GST-WT1 protein ( Figure 4a ) and in vitro translated 35 S-labelled hnRNP-U, with in vitro translated luciferase as a negative control. The GST-binding assays show that hnRNP-U directly interacts with fulllength WT1, that the association is mediated through the zinc-fingers of WT1 rather than the N-terminus (Figure 4b ) and does not require other proteins or nucleic acids. The specificity of this in vitro interaction was confirmed by the observation that the in vitro translated luciferase does not interact with any of the GST-WT1 constructs, nor does the translated hnRNP-U interact with the GST affinity column (Figure 4b ).
The multifunctional properties of hnRNP-U have previously been mapped to specific domains within the protein (Figure 4c ). The N-terminal domain (acidic and glutamine rich) is important for interaction with nuclear matrix and chromatin, whereas the RGG box-containing C-terminal domain is important for interaction with other hnRNP proteins to form hnRNP particles (PinolRoma et al., 1988; Kiledjian and Dreyfuss, 1992) . The middle domain mediates the interaction of hnRNP-U with RNA polymerase II, and its association results in inhibition of TFIIH-mediated phosphorylation and RNA polymerase II elongation (Kim and Nikodem, 1999) . To determine which domain of hnRNP-U interacts with WT1, HA-tagged hnRNP-U proteins (indicated in Figure 4c ) were co-expressed in Cos-7 cells with T7-tagged full-length WT1, including exon 5 and the KTS insert (Figure 4d[i] ). Extracts from Cos-7 cells co-transfected with T7-tagged WT1 ( þ / þ ) and HAtagged hnRNP-U constructs were immunoprecipitated with the anti-WT1 rabbit polyclonal C-19 antibody and probed by Western blot with the anti-HA mouse monoclonal antibody. Full-length (hnRNP-U FL) and middle domain (hnRNP-U M) hnRNP-U proteins coimmunoprecipitated with WT1, demonstrating that the middle domain is sufficient to mediate the interaction of hnRNP-U with WT1 ( Figure 4d [ii]). Similar results were obtained using the T7-tagged full-length WT1 including 
antibody (C, ES cells; D, M15 cells). (e)
Colocalization of WT1 and hnRNP-U proteins. Endogenous expression of WT1 protein (red) and hnRNP-U protein (green) was determined by indirect immunofluoresence in M15 cell lines as previously described (Ladomery et al., 1999) , using C-19 and 3G6 antibodies and visualized with deconvolution fluorescence microscopy. Three-dimensional (3D)-immunolocalization of the endogenous proteins was preformed by the acquisition of Z-axis stacks (0.2 mcm) using the Delta Vision Soft Worx software. The deconvolved two-channel 3D image was exported to ImarisColoc for quantitative analysis. The calculated colocalization channel was built using surface rendering techniques of ImarisSurpass, with colocalization volume displayed in white. The percent of the red channel volume colocalized with green was calculated for n ¼ 5 nuclei and is given as a mean value 7s.d. in the upper left corner. The Pearson channel correlation in colocalized volume is given in the upper right corner (1 ¼ perfect colocalisation, 0 ¼ no correlation). (f) Colocalization of WT1 and hnRNP-U during nephrogenesis. Endogenous expression of WT1 protein (green) and hnRNP-U protein (red) was determined by indirect immunofluoresence in mouse E16.5 fetal kidneys using the C-19 and 3G6 antibodies. We were unable to assess the hnRNP-U C mutant protein fragment in IP experiments, as though it was expressed at high levels ( Figure 4d [i]), we were unable to isolate it in nuclear extracts as it remained in the insoluble fraction. Thus, we cannot exclude an interaction between WT1 and the C-terminus of hnRNP-U. For the immunoprecipitations, essentially similar results were obtained in the M15 cell line (data not shown).
To confirm the finding from the IP experiments, 3D deconvolution fluorescence microscopy with quantitative colocalization was carried out with WT1 and the HA-tagged hnRNP-U constructs (Heilbronn et al., 2003) . Acquisition of the Z-axis stacks (0.2 mcm) of the images in either fluorescence channel was performed followed by Imaris-Colocalization quantitative analysis. The results support the findings of the IP experiments as full-length hnRNP-U and hnRNP-U M both colocalized with WT1 (88% of the red channel volume, WT1, colocalized with the green channel, hnRNP-U, for both), whereas hnRNP-U N did not (only 6% of the red channel, WT1, colocalized with the green channel, hnRNP-U) (Figure 4e ). hnRNP-U C could partially colocalize with WT1 (volume colocalization 64%) leaving open the possibility for existence of WT1-binding site in the C-terminus of hnRNP-U. Similar results were obtained using M15 cells (data not shown) -the middle domain and full-length hnRNP-U colocalize with WT1.
To investigate the functional consequences of this interaction, we next assessed whether hnRNP-U could regulate WT1 transcriptional activity of the amphiregulin promoter, a bona fide WT1 transcriptional target previously shown to be activated by transfection of WT1 (Lee et al., 1999) . A luciferase reporter gene under the control of the amphiregulin promoter, with and without WT1-binding sites, was transfected into NIH 3T3 cells in the presence or absence of hnRNP-U. As previously described, WT1 activated reporter gene expression (Figure 4f) (Carpenter et al., 2004) . However, cotransfection with hnRNP-U significantly reduced (50%) (Po0.0000175 and 0.000145) WT1 activation, but had little effect when transfected alone (Figure 4f ) and did not affect expression of WT1 itself -WT1 protein is still highly expressed in the presence of transfected hnRNP-U (Figure 4e ). Minimal activation was detected from the amphiregulin promoter lacking WT1-binding sites, confirming that these transcriptional effects are mediated through WT1 (Figure 4f) . Similar results were obtained in the HeLa cell line (data not shown), demonstrating that hnRNP-U can specifically repress WT1-mediated transcriptional activation.
To summarize, we have shown that hnRNP-U is a bona fide binding partner of WT1. The endogenous proteins physically interact via the zinc-fingers of WT1 and the middle domain of hnRNP-U, the interaction is direct and hnRNP-U can inhibit WT1-mediated transcriptional activation. hnRNP-U has been shown to regulate splicing and RNA transport as well as transcription (Kanai et al., 2004; Kukalev et al., 2005) . Similar roles have been proposed for WT1 (Davies et al., 1998; Ladomery et al., 1999; Niksic et al., 2004) , so the interaction with hnRNP-U could potentially regulate any of these processes. However, the involvement of the middle domain of hnRNP-U and the modulation of Figure 4 Domains of association and affects of hnRNP-U on WT1 transcriptional activation. (a) Schematic representation of the GST-WT1 expression constructs. Construction and use of GST-WT1 bacterial expression vectors has been previously described (Lee et al., 2002) . GST-WT1 (FL) represents full-length WT1 protein (amino acids 1-446) including exon 5 insert and excluding the KTS insert. represents the N-terminal region of WT1 protein (amino acids 1-242). GST-WT1 (C) represents the C-terminal region of the WT1 protein (amino acids 297-446) which covers the zinc-finger region (excluding KTS insert). (b) hnRNP-U interacts with the zinc-finger domain of WT1. GST and GST-WT1 recombinant proteins were purified as described previously (Lee et al., 2002) .
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S-methionine-labelled hnRNP-U or Luciferase was prepared using the TNT-coupled Transcription/Translation system (Promega) as per the manufacturer's instructions.
S-methionine-labelled hnRNP-U or Luciferase were incubated with GST or GST-WT1 recombinant proteins. Captured proteins were resolved and visualized by autoradiography. (c) Schematic representation of HA-tagged hnRNP-U expression constructs. Construction of the HA-tagged hnRNP-U constructs were generated as previously described (Kim and Nikodem, 1999) (d) [ii] Nuclear extracts prepared from transfected Cos-7 cells were immunoprecipitated with anti-WT1 rabbit polyclonal antibody (C-19; Santa Cruz). WT1 immunoprecipitations were resolved and probed with an anti-HA mouse monoclonal antibody (Calbiochem). (e) Indirect immunofluorescence for WT1 (red) and hnRNP-U (green) was carried out on transiently transfected Cos-7 cells as previously described (Ladomery et al., 1999; Niksic et al., 2004) . 3D-immunolocalization of the transfected proteins was preformed by the acquisition of Z-axis stacks (0.2 mcm) using Delta Vision Soft Worx software. The deconvolved two-channel 3D image was exported to ImarisColoc for quantitative analysis. The calculated colocalization channel was built using surface rendering techniques of ImarisSurpass with colocalization volumes displayed in white (a-d). The percent of the red channel volume colocalized with green was calculated for n ¼ 5 nuclei and is given as a mean value7s.d. in the upper left corner (a-d). The Pearson channel correlation in colocalized volume is given in the upper right corner (1 ¼ perfect colocalization, 0 ¼ no correlation). (f) hnRNP-U represses WT1 transcriptional activity. NIH3T3 cells were transfected with the amphiregulin promoter reporter construct containing or lacking the WRE-binding site (Amphiregulin-Luc7WRE), along with (1) WT1 (7) isoforms (blue) or WT1 (À/À) (red), (2) hnRNP-U (FL), (3) hnRNP-U (FL) and WT1 (7) or hnRNP-U (FL) and WT1 (À/À) or (4) empty vector (pcDNA3.1, Invitrogen). NIH3T3 cells were transfected with the various DNA vectors using Lipofectamine 2000, following the manufacturer's instructions (Invitrogen). All transfections were carried out using same amount of DNA, with the addition of empty expression vector (pcDNA3.1; Invitrogen) to equalize all transfections. Experiments were carried out in triplicate.
[i] Luciferase activity was assayed after 48 h using the Promega Luciferase Assay Kit (Promega) as per the manufacturer's instructions. The error bars represent the s.d. of three independent experiments. The results were analysed using Student's t-test. P-values o0.05 were considered significant.
[ii] NIH3T3 whole-cell extracts were immunoblotted with both anti-WT1 antibody and anti-hnRNP-U antibody to show the levels of expression of transfected WT1 and hnRNP-U.
hnRNP-U modulates WT1 transcriptional activation L Spraggon et al WT1 transcriptional activity suggests that, notwithstanding other functions, this interaction is involved in the regulation of transcription. hnRNP-U has been shown to associate with the RNA polymerase II complex and is recruited to promoters as part of the pre-initiation complex (Kim and Nikodem, 1999) , but dissociates from the complex at an early stage of transcription and is absent from the elongation competent complex. hnRNP-U represses transcription by inhibiting the kinase activity of TFIIH and preventing the phosphorylation of the CTD (Kim and Nikodem, 1999) . This transcriptional inhibition by hnRNP-U was shown to involve the middle domain of hnRNP-U, the same domain that associates with WT1, suggesting that the hnRNP-U:WT1 interaction may mediate transcriptional inhibition by bringing hnRNP-U into the proximity of RNA polymerase II via WT1-binding sites in the promoters of target genes. In addition, a search for novel actin-binding proteins associated with RNA polymerase II identified hnRNP-U (Kukalev et al., 2005) and showed that both actin and hnRNP-U associate with the phosphorylated form of RNA polymerase II and are implicated in the initial phases of transcription. In the present study, we also detected a protein that matched either g-or b-actin in the MS-FIT database as immunoprecipitating with WT1 (Table 2 .1). While this interaction remains to be verified, it is possible that WT1, hnRNP-U and g/b-actin are present in a single complex that regulates transcription.
Finally, hnRNP-U is located at human chromosome 1q44. It is intriguing to note that gain of chromosome 1q is a common feature of Wilms' tumour and that this is not solely gain of the well-documented 1q20-25 region (Williams et al., 2004) . In fact, approximately 30% of Wilms' tumours have gain of 1q encompassing 1q44, with some of those tumours showing focal 1q44 gain (Dr Chris Jones and Dr Kathy Pritchard-Jones, personal communication). This, together with our findings that hnRNP-U interacts with WT1 and can inhibit WT1-mediated transcriptional activation of a kidney-specific target gene, amphiregulin, suggests that excess hnRNP-U may inhibit WT1 activity in Wilms' tumours lacking WT1 mutation.
